LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Inicio・Lista de Acciones・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Cerrado

SectorSanidad

218.15 4.49

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

207.85

Máximo

228

Métricas clave
By Trading Economics
Ingresos	-22M -61M
Ventas	56M 214M
Margen de beneficios	-28.549
Empleados	1,017
EBITDA	-56M -53M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+18.24% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	785M 13B
Apertura anterior	213.66
Cierre anterior	218.15

Noticias sobre sentimiento de mercado

By Acuity

50%

158 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

157.66 / 167.29 Soporte y Resistencia

Ascendis Pharma A-S ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 dic 2025, 22:53 UTC

Adquisiciones, fusiones, absorciones

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13 dic 2025, 00:04 UTC

Adquisiciones, fusiones, absorciones

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14 dic 2025, 23:46 UTC

Charlas de Mercado

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14 dic 2025, 23:36 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14 dic 2025, 22:38 UTC

Adquisiciones, fusiones, absorciones

Fortescue to Take Full Control of US$101M Copper Miner Alta

14 dic 2025, 22:02 UTC

Adquisiciones, fusiones, absorciones

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14 dic 2025, 22:01 UTC

Adquisiciones, fusiones, absorciones

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14 dic 2025, 22:01 UTC

Adquisiciones, fusiones, absorciones

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14 dic 2025, 22:00 UTC

Adquisiciones, fusiones, absorciones

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14 dic 2025, 22:00 UTC

Adquisiciones, fusiones, absorciones

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14 dic 2025, 21:59 UTC

Adquisiciones, fusiones, absorciones

Fortescue to Acquire Remaining 64% of Alta Copper

14 dic 2025, 17:00 UTC

Ganancias

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14 dic 2025, 08:30 UTC

Adquisiciones, fusiones, absorciones

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13 dic 2025, 16:48 UTC

Adquisiciones, fusiones, absorciones

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 08:00 UTC

Adquisiciones, fusiones, absorciones

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 07:00 UTC

Adquisiciones, fusiones, absorciones

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 dic 2025, 00:24 UTC

Adquisiciones, fusiones, absorciones

Want a Piece Of SpaceX? -- Barrons.com

12 dic 2025, 23:49 UTC

Adquisiciones, fusiones, absorciones

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dic 2025, 22:52 UTC

Charlas de Mercado

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dic 2025, 22:32 UTC

Ganancias

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 dic 2025, 20:45 UTC

Ganancias

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dic 2025, 20:41 UTC

Charlas de Mercado

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dic 2025, 20:20 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dic 2025, 19:23 UTC

Ganancias

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dic 2025, 18:35 UTC

Adquisiciones, fusiones, absorciones

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dic 2025, 18:33 UTC

Adquisiciones, fusiones, absorciones

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dic 2025, 18:31 UTC

Charlas de Mercado

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dic 2025, 17:49 UTC

Ganancias

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dic 2025, 17:34 UTC

Adquisiciones, fusiones, absorciones

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR previsión

Precio Objetivo

By TipRanks

18.24% repunte

Estimación a 12 Meses

Media 260.62 USD 18.24%

Máximo 325 USD

Mínimo 220 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

158 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.